DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 213 filers reported holding DENALI THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,060,524 | -30.1% | 99,880 | 0.0% | 0.04% | -27.6% |
| Q2 2023 | $2,947,459 | +28.1% | 99,880 | 0.0% | 0.06% | +11.5% |
| Q1 2023 | $2,301,235 | -17.2% | 99,880 | 0.0% | 0.05% | -20.0% |
| Q4 2022 | $2,777,663 | -9.4% | 99,880 | 0.0% | 0.06% | -19.8% |
| Q3 2022 | $3,065,000 | +4.3% | 99,880 | 0.0% | 0.08% | +14.1% |
| Q2 2022 | $2,939,000 | -8.5% | 99,880 | 0.0% | 0.07% | +1.4% |
| Q1 2022 | $3,213,000 | -27.9% | 99,880 | 0.0% | 0.07% | -27.1% |
| Q4 2021 | $4,455,000 | -11.7% | 99,880 | -0.1% | 0.10% | -17.9% |
| Q3 2021 | $5,045,000 | -16.7% | 100,000 | +29.5% | 0.12% | -16.4% |
| Q2 2021 | $6,056,000 | +86.1% | 77,200 | +35.4% | 0.14% | +57.3% |
| Q1 2021 | $3,255,000 | +159.2% | 57,000 | +280.0% | 0.09% | +111.9% |
| Q4 2020 | $1,256,000 | – | 15,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |